MCCORMICK & CO INC

**Signal Note:** Eventide's entry into McCormick (MKC) signals a values-aligned diversification move rather than a biotech catalyst play—the position reflects their ESG framework rather than pipeline developments. This $857K stake is immaterial to their $5.3B AUM and suggests portfolio rebalancing into consumer staples rather than conviction on company-specific biotech or clinical catalysts. The trade carries no obvious near-term drug development or regulatory catalyst.